Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Metomidate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 7/20 | 0.72 |
| ▸ | GABRB2 known ✓ | P47870 | 6/20 | 0.72 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.72 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metomidate SCHEMBL4377172 | 0.99 | MAPK1 (0.97) | MAPK1GABRA1GABRB2CYP11B1CYP11B2 | |
| Metomidate SCHEMBL491910 | 0.99 | MAPK1 (0.97) | MAPK1GABRA1GABRB2CYP11B1CYP11B2 | |
| Metomidate SCHEMBL11733503 | 0.93 | MAPK1 (0.88) | MAPK1GABRA1GABRB2CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL11334431 | 0.87 | MAPK1 (0.78) | MAPK1GABRA1GABRB2CYP11B1CYP11B2 | |
| SCHEMBL19062800 | 0.86 | MAPK1 (0.76) | MAPK1GABRA1GABRB2CYP11B1CYP11B2 | |
| SCHEMBL15125287 | 0.86 | MAPK1 (0.76) | MAPK1GABRA1GABRB2CYP11B1CYP11B2 | |
| SCHEMBL15125277 | 0.86 | MAPK1 (0.76) | MAPK1GABRA1GABRB2CYP11B1CYP11B2 | |
| SCHEMBL22004285 | 0.86 | MAPK1 (0.76) | MAPK1GABRA1GABRB2CYP11B1CYP11B2 | |
| SCHEMBL31406537 | 0.86 | MAPK1 (0.76) | MAPK1GABRA1GABRB2CYP11B1CYP11B2 | |
| SCHEMBL18265957 | 0.86 | MAPK1 (0.75) | MAPK1GABRA1GABRB2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4460178-A1 | METHOD TO DETACH ECTOPARASITES FROM FISH | Intervet International B.V. (NL) | 2024-11-13 | — | — | EP | disclosed |
| WO-2023131615-A1 | METHOD TO DETACH ECTOPARASITES FROM FISH | INTERVET INTERNATIONAL B.V. (NL) | 2023-07-13 | — | — | WO | disclosed |
| US-20230001128-A1 | AEROSOLIZATION SYSTEMS, METHODS, AND APPARATUSES | SHUSTER GARY STEPHEN (CA) | 2023-01-05 | — | — | US | disclosed |
| EP-3424536-B1 | ANAESTHETIC SOLUTION AND METHOD OF USE THEREOF FOR ANAESTHETISING, STUNNING AND SLAUGHTERING FISH | UNIV CARTAGENA POLITECNICA (ES) | 2021-01-27 | — | — | EP | disclosed |
| EP-3424536-A1 | ANAESTHETIC SOLUTION AND METHOD OF USE THEREOF FOR ANAESTHETISING, STUNNING AND SLAUGHTERING FISH | Universidad Politecnica de Cartagena (ES) | 2019-01-09 | — | — | EP | disclosed |
| US-8865197-B2 | Food formulation for aquatic animals with integrated targeted delivery of bioactive agents | ISRAEL OCEANOGRAPHIC AND LIMNOLOGICAL RESEARCH LTD. (IL) | 2014-10-21 | — | — | US | disclosed |
| EP-1941872-B1 | Use of TNF-alpha inhibitors for treating nerve root injury | SCIATICON AB (SE) | 2013-04-10 | — | — | EP | disclosed |
| US-20120244157-A1 | USE OF TNF-ALPHA INHIBITORS FOR TREATING A NERVE DISORDER MEDIATED BY NUCLEUS PULPOSUS | SCIATICON AB (SE) | 2012-09-27 | — | — | US | disclosed |
| EP-2324843-A1 | Use of TNF-alpha inhibitors for treating nerve root injury | Sciaticon AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100305048-A1 | NOVEL USE OF CYTOKINE INHIBITORS | PHARMASURGICS IN SWEDEN AB (SE) | 2010-12-02 | — | — | US | disclosed |
| US-20010055594-A1 | Use of certain drugs for treating nerve root injury | SCIATICON AB (SE) | 2001-12-27 | — | — | US | disclosed |
| US-20010027175-A1 | Use of certain drugs for treating nerve root injury | A + SCIENCE AB (PUBL) (SE) | 2001-10-04 | — | — | US | disclosed |
| US-20010027199-A1 | Use of certain drugs for treating nerve root injury | SCIATICON AB (SE) | 2001-10-04 | — | — | US | disclosed |
| EP-1115405-A1 | USE OF CERTAIN DRUGS FOR TREATING NERVE ROOT INJURY | A+ Science Invest AB (SE) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000075659-A1 | ANTIBODIES TO NUCLEUS PULPOSUS IN DISC HERNIATION, DIAGNOSTIC KIT, MEDICAL PREPARATIONS AND TREATMENT | A+SCIENCE INVEST AB (SE) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000018409-A1 | USE OF CERTAIN DRUGS FOR TREATING NERVE ROOT INJURY | A+ SCIENCE INVEST AB (SE) | 2000-04-06 | — | — | WO | disclosed |
| US-5639457-A | INTRODUCING DNA SEQUENCE CODING FOR REARRANGED ANTIBODY INTO MALE PRONUCLEUS OF FERTILIZED OVUM; IMPLANTING IN PIG OR RABBIT; TRANSGENIC OFFSPRING PRODUCE ANTIBODIES | Brem, Gottfried (DE) | 1997-06-17 | — | — | US | disclosed |
| US-5221734-A | Separation by chromatography | CIBA-GEIGY CORPORATION (US) | 1993-06-22 | — | — | US | disclosed |
| EP-0313515-B1 | A POLYPEPTIDE GROWTH FACTOR FROM MILK | CIBA-GEIGY AG (CH) | 1992-03-11 | — | — | EP | disclosed |
| EP-0313515-A1 | A polypeptide growth factor from milk | CIBA-GEIGY AG (CH) | 1989-04-26 | — | — | EP | disclosed |